TXA may benefit stroke patients
Patients with stroke caused by bleeding on the brain may benefit from receiving a drug currently used to treat blood loss from major trauma and bleeding after childbirth...
List view / Grid view
Patients with stroke caused by bleeding on the brain may benefit from receiving a drug currently used to treat blood loss from major trauma and bleeding after childbirth...
Algenuity, a leader in algal biology and industrial biotechnology, is delighted to welcome Dr Alex Pudney to the team as Chief Scientific Officer...
Researchers have found that nintedanib shows promising effectiveness in halting the growth of human malignant pleural mesothelioma in preclinical models.
The NIH is supporting efforts to broaden biomedical scientists’ access to cryo-electron microscopy, the imaging method that is revolutionising structural biology...
Discovery of a pathway linking Alzheimer's disease and Type 2 diabetes leads to new strategies to preserve brain health...
The FDA has approved Retacrit as a biosimilar to Epogen/Procrit for the treatment of anaemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection...
An international team of scientists have developed a novel tool to accurately predict eye, hair and skin colour from human biological material...
Researchers describe how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome...
New catalyst is specifically tuned to integrate fluorine atoms into a new organic product...
The FDA has approved Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older...
The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack and stroke...
By engineering a special molecule to track certain immune cells in the body, scientists have invented a litmus test for the effectiveness of a newly devised cancer therapy...
The approval provides paediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one...
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
Researchers synthesized self-assembling peptide amphile nanofibers that targeted areas of plaque and could be delivered by intravenous injection...